Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently bought shares of Revvity Inc. (NYSE:RVTY). In a filing disclosed on June 08th, the Representative disclosed that they had bought between $15,001 and $50,000 in Revvity stock on May 4th. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.
Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):
- Purchased $1,001 – $15,000 in shares of SoftBank Group (OTCMKTS:SFTBF) on 6/2/2026.
- Purchased $1,001 – $15,000 in shares of Ciena (NYSE:CIEN) on 5/29/2026.
- Sold $1,001 – $15,000 in shares of AutoZone (NYSE:AZO) on 5/29/2026.
- Purchased $1,001 – $15,000 in shares of Independent Bank (NASDAQ:INDB) on 5/29/2026.
- Purchased $1,001 – $15,000 in shares of Arcutis Biotherapeutics (NASDAQ:ARQT) on 5/29/2026.
- Purchased $1,001 – $15,000 in shares of HealthEquity (NASDAQ:HQY) on 5/29/2026.
- Purchased $1,001 – $15,000 in shares of Boston Scientific (NYSE:BSX) on 5/29/2026.
- Purchased $1,001 – $15,000 in shares of Perella Weinberg Partners (NASDAQ:PWP) on 5/29/2026.
- Purchased $1,001 – $15,000 in shares of Cooper Companies (NASDAQ:COO) on 5/29/2026.
- Purchased $1,001 – $15,000 in shares of Ligand Pharmaceuticals (NASDAQ:LGND) on 5/29/2026.
Revvity Trading Down 1.8%
RVTY traded down $1.81 during trading on Thursday, reaching $99.48. The company had a trading volume of 148,307 shares, compared to its average volume of 1,329,806. Revvity Inc. has a 12-month low of $81.22 and a 12-month high of $118.30. The firm’s 50-day simple moving average is $94.40 and its 200 day simple moving average is $97.72. The company has a market cap of $11.10 billion, a price-to-earnings ratio of 47.89, a PEG ratio of 2.28 and a beta of 1.11. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.41 and a current ratio of 1.72.
Revvity Announces Dividend
The business also recently announced a quarterly dividend, which will be paid on Friday, August 7th. Stockholders of record on Friday, July 17th will be given a dividend of $0.07 per share. The ex-dividend date of this dividend is Friday, July 17th. This represents a $0.28 dividend on an annualized basis and a dividend yield of 0.3%. Revvity’s payout ratio is 13.40%.
Analysts Set New Price Targets
Several equities research analysts have issued reports on RVTY shares. Barclays increased their price target on Revvity from $95.00 to $105.00 and gave the stock an “equal weight” rating in a report on Thursday, May 7th. JPMorgan Chase & Co. dropped their target price on shares of Revvity from $96.00 to $90.00 and set a “neutral” rating on the stock in a report on Wednesday, May 6th. TD Cowen increased their target price on Revvity from $115.00 to $120.00 and gave the stock a “buy” rating in a report on Wednesday, May 6th. Stifel Nicolaus decreased their target price on shares of Revvity from $110.00 to $100.00 and set a “hold” rating for the company in a research note on Wednesday, May 6th. Finally, Robert W. Baird set a $117.00 target price on shares of Revvity in a report on Wednesday, May 6th. Four investment analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Revvity currently has a consensus rating of “Hold” and a consensus target price of $107.73.
Get Our Latest Report on Revvity
Institutional Inflows and Outflows
Several large investors have recently added to or reduced their stakes in the company. AQR Capital Management LLC increased its position in Revvity by 5.2% during the first quarter. AQR Capital Management LLC now owns 8,449 shares of the company’s stock worth $883,000 after acquiring an additional 420 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of Revvity by 6.7% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 11,776 shares of the company’s stock valued at $1,246,000 after buying an additional 744 shares during the period. Millennium Management LLC increased its stake in Revvity by 102.0% during the 1st quarter. Millennium Management LLC now owns 69,401 shares of the company’s stock worth $7,343,000 after acquiring an additional 35,048 shares during the period. Goldman Sachs Group Inc. lifted its position in shares of Revvity by 45.5% during the 1st quarter. Goldman Sachs Group Inc. now owns 607,104 shares of the company’s stock valued at $64,232,000 after acquiring an additional 189,871 shares during the period. Finally, Focus Partners Wealth grew its holdings in shares of Revvity by 13.0% during the 1st quarter. Focus Partners Wealth now owns 7,028 shares of the company’s stock worth $744,000 after purchasing an additional 811 shares in the last quarter. Institutional investors own 86.65% of the company’s stock.
About Representative Cisneros
Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.
Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.
Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.
About Revvity
Revvity, Inc is a global provider of technology-enabled solutions for the life sciences, diagnostics and applied markets. The company develops and supplies a range of products and services, including reagents and consumables, laboratory instruments, workflow automation, software analytics and technical support. Its portfolio supports applications in drug discovery, genomics, cell biology research, environmental and food safety testing, industrial quality control and clinical diagnostics.
Tracing its heritage to Perkin-Elmer, founded in 1937, Revvity began trading on the New York Stock Exchange under the ticker symbol RVTY in January 2024 following a corporate rebranding.
Further Reading
- Five stocks we like better than Revvity
- SpaceX IPO Fears Are Overblown, But the AI Bet Is Real
- 3 Stocks Cashing In on AI While Everyone Watches NVIDIA
- 2 Ways to Play the QXO/TopBuild Deal
- Wolfspeed Ditches EV Woes for High-Margin Defense Jets
Receive News & Ratings for Revvity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revvity and related companies with MarketBeat.com's FREE daily email newsletter.
